CRBU Stock Risk & Deep Value Analysis
Caribou Biosciences Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CRBU Stock
We analyzed Caribou Biosciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CRBU through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CRBU Risk Analysis & Red Flags
What Could Go Wrong
The significant cash burn rate of $200-$220 million for 2026 implies a severe need for capital. If Caribou fails to secure sufficient funding through partnerships or equity raises on favorable terms, or if such raises cause excessive dilution, the company's ability to advance its promising pipeline could be jeopardized, leading to a substantial stock price decline.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Deeply negative profitability with a -1,327.40% net margin for Q4 2025.
- ⚠
High cash burn rate guidance of $200–220 million for 2026.
- ⚠
Mention of 'insider net selling' as a risk factor, potentially signaling lack of insider confidence.
- ⚠
All lead programs (CB-010, CB-011, CB-012) remain in early-stage Phase 1 trials, indicating high clinical and regulatory risk.
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results for any lead candidate
- 📅
Failure to secure adequate financing leading to significant dilution or pipeline delays
- 📅
Intensified competition from rival allogeneic CAR-T platforms
When to Reconsider
- 🚪
Failure of a pivotal clinical readout (e.g., CB-010 or CB-011 Phase 1/2 data showing poor efficacy or safety).
- 🚪
Inability to secure the next round of financing, or a capital raise that causes excessive (>25%) dilution to existing shareholders.
- 🚪
Significant acceleration in cash burn without corresponding positive clinical milestones.
Unlock CRBU Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Caribou Biosciences Inc (CRBU) Do?
Market Cap
$212.60M
Sector
Healthcare
Industry
Biotechnology
Employees
147
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Visit Caribou Biosciences Inc WebsiteInvestment Thesis
Caribou Biosciences is a high-conviction play on the next generation of allogeneic CAR-T cell therapies, driven by its differentiated CRISPR genome-editing platform. The recent FDA RMAT designation for CB-011, combined with robust early clinical data, significantly enhances its long-term potential for market leadership in multiple myeloma and validates its technological approach. Despite high financial risk from cash burn, successful execution and clinical progression could unlock substantial value, offering 10x growth potential as it advances towards commercialization.
Is CRBU Stock Undervalued?
Unlock the full AI analysis for CRBU
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CRBU Price Targets & Strategy
12-Month Target
$9.00
Bull Case
$15.00
Bear Case
$1.00
Valuation Basis
Based on 50x forward P/S applied to estimated FY2027 revenue of $15.4M, with a post-dilution share count of ~100M shares.
Entry Strategy
Dollar-cost average between $2.00-$2.50, establishing a position at current support levels after the RMAT news-driven rally. Consider dips towards the $2.00 level.
Exit Strategy
Take partial profit at $9.00 (median analyst target), with a stop-loss order placed below $1.50 if critical clinical milestones are missed or financing terms are highly dilutive.
Portfolio Allocation
5-7% for aggressive risk tolerance (given the early-stage biotech profile).
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is CRBU Financially Healthy?
Valuation
P/E Ratio
-0.80
EV/EBITDA
-0.74
PEG Ratio
0.05
Price/Book
0.50
Price/Sales
11.90
Profitability
Operating Margin
-1411.43%
Net Margin
-1327.40%
Return on Equity
-91.52%
Revenue Growth
11.66%
EPS
$-1.59
Balance Sheet
Current Ratio
5.71
Quick Ratio
5.60
Total Debt
$25.46M
Cash & Equivalents
$147.26M
Cash Flow
Operating Cash Flow
-$125.64M
Free Cash Flow
-$127.73M
EBITDA
-$135.69M
Other
Beta (Volatility)
2.50
Does CRBU Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is durable due to Caribou's proprietary CRISPR genome-editing technology, which is fundamental to its 'off-the-shelf' approach. As clinical successes mount and regulatory designations like RMAT are achieved, the value and defensibility of this IP strengthen, making it harder for competitors to replicate.
Moat Erosion Risks
- •Rapid advancements by competitors in gene-editing or allogeneic cell therapies.
- •Potential intellectual property challenges or litigation.
- •Failure of late-stage clinical trials, diminishing the value of the platform.
CRBU Competitive Moat Analysis
Sign up to see competitive advantages
CRBU Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish, fueled by positive clinical news and the potential for a disruptive technology.
Institutional Sentiment
Positive, evidenced by Truist Financial's upgrade to 'Strong Buy' on March 25, 2026, and HC Wainwright's reaffirmation of 'Buy' with a $9.00 price target on April 7, 2026.
Insider Activity (Form 4)
One source notes 'insider net selling' as a risk factor; however, specific transaction details (names, amounts) are not provided in the research.
Options Flow
Normal options activity; no specific unusual option flows indicating significant institutional positioning were provided in the research.
Earnings Intelligence
Next Earnings
2026-05-12
Surprise Probability
Medium
Historical Earnings Pattern
The stock reacted positively to the Q4 2025 earnings beat and surged 10.5% following the RMAT designation announcement, suggesting a positive reaction to favorable news and clinical progress.
Key Metrics to Watch
Competitive Position
Top Competitor
Iovance Biotherapeutics (IOVA)
Market Share Trend
Too early to assess market share, as lead products are still in Phase 1 trials.
Valuation vs Peers
CRBU's P/S ratio (18.416) is significantly lower than the sector median for comparable stocks (325.679), suggesting it could be undervalued relative to its potential, though its current revenue base is minimal. Direct valuation comparison is challenging due to varying clinical stages.
Competitive Advantages
- •Proprietary CRISPR genome-editing (chRDNA) platform enabling 'off-the-shelf' therapies
- •Early clinical data for CB-011 (Multiple Myeloma) showing high response rates (92% ORR)
- •FDA RMAT designation for CB-011, expediting regulatory pathway
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive CRBU Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings on May 12, 2026
- •Further clinical data updates for CB-010, CB-011, or CB-012 in 2026
- •2026 Annual Meeting of Stockholders on June 17, 2026
Medium-Term (6-18 months)
- •Progression of CB-011 into later-stage clinical trials
- •Potential strategic partnerships or licensing deals for pipeline assets
- •Successful scale-up of CB-010 manufacturing
Long-Term (18+ months)
- •Commercialization of CB-010 or CB-011 in oncology markets
- •Expansion of pipeline into new therapeutic areas using the chRDNA platform
- •Establishment as a market leader in allogeneic CAR-T therapy
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CRBU?
- ✓
Positive clinical data readouts from CB-010 and CB-011 Phase 1/2 trials.
- ✓
Successful and non-dilutive (or minimally dilutive) capital raises.
- ✓
Formation of significant strategic partnerships or licensing agreements.
Bull Case Analysis
See what could go right with Premium
Competing with CRBU
See how Caribou Biosciences Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Caribou Biosciences Inc CRBU | $212.6M | 7.2 | -0.8 | $9.3M | -1327.4% | 11.7% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Caribou Biosciences Inc Makes Money
Caribou Biosciences is a clinical-stage biotechnology company developing universal, 'off-the-shelf' CAR-T cell therapies for cancer. Unlike personalized treatments that use a patient's own cells, Caribou leverages its proprietary CRISPR genome-editing technology to engineer donor-derived cells, making these advanced therapies more broadly accessible, scalable, and potentially more cost-effective. The company currently generates minimal revenue, relying on research grants and collaborations, with its future entirely dependent on the successful clinical development, regulatory approval, and eventual commercialization or out-licensing of its drug candidates.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Caribou Biosciences Inc (CRBU)?
As of April 21, 2026, Caribou Biosciences Inc has a DVR Score of 7.2 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Caribou Biosciences Inc?
Caribou Biosciences Inc's market capitalization is approximately $212.6M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Caribou Biosciences Inc use?
CRBU is the ticker symbol for Caribou Biosciences Inc. The company trades on the NMS.
What is the risk level for CRBU stock?
Our analysis rates Caribou Biosciences Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CRBU?
Caribou Biosciences Inc currently has a price-to-earnings (P/E) ratio of -0.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Caribou Biosciences Inc's revenue growing?
Caribou Biosciences Inc has reported revenue growth of 11.7%. The company is showing strong top-line momentum.
Is CRBU stock profitable?
Caribou Biosciences Inc has a profit margin of -1327.4%. The company is currently unprofitable.
How often is the CRBU DVR analysis updated?
Our AI-powered analysis of Caribou Biosciences Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 21, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CRBU (Caribou Biosciences Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.